| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | adc |
| Uniprot No | P23670 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-244aa |
| 氨基酸序列 | MLKDEVIKQISTPLTSPAFPRGPYKFHNREYFNIVYRTDMDALRKVVPEPLEIDEPLVRFEIMAMHDTSGLGCYTESGQAIPVSFNGVKGDYLHMMYLDNEPAIAVGRELSAYPKKLGYPKLFVDSDTLVGTLDYGKLRVATATMGYKHKALDANEAKDQICRPNYMLKIIPNYDGSPRICELINAKITDVTVHEAWTGPTRLQLFDHAMAPLNDLPVKEIVSSSHILADIILPRAEVIYDYLK |
| 预测分子量 | 35.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与ADC(抗体药物偶联物)重组蛋白技术相关的模拟参考文献示例，内容基于领域研究趋势归纳而成：
---
1. **文献名称**: *"Engineering Recombinant Antibodies for Next-Generation Antibody-Drug Conjugates"*
**作者**: Smith J, et al.
**摘要**: 探讨利用重组抗体技术优化ADC的靶向性和稳定性，通过基因工程改造Fc区域和抗原结合位点，增强药物载荷传递效率并降低脱靶毒性。
2. **文献名称**: *"Recombinant Linker Design Enhances Stability and Payload Release of ADCs"*
**作者**: Chen L, et al.
**摘要**: 研究重组技术设计新型可裂解连接子，通过计算机模拟和体外实验验证其在ADC中的可控释放特性，提高肿瘤细胞内药物释放效率。
3. **文献名称**: *"High-Yield Production of ADCs Using Mammalian Cell Expression Systems"*
**作者**: Gupta R, et al.
**摘要**: 分析哺乳动物细胞表达系统在重组抗体-药物偶联物规模化生产中的应用，优化糖基化修饰以提高ADC的药代动力学特性。
---
**注**：以上文献为示例性内容，实际引用时需核实具体论文信息。建议通过PubMed或Web of Science以关键词“recombinant ADC”、“antibody-drug conjugate engineering”检索最新研究。
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics designed to deliver cytotoxic drugs specifically to cancer cells while minimizing systemic toxicity. Central to ADC development are recombinant proteins, particularly monoclonal antibodies (mAbs), engineered via genetic recombination techniques. Recombinant protein technology enables the precise customization of antibody structure, antigen-binding domains, and conjugation sites, which are critical for ADC stability, efficacy, and safety.
The concept of ADCs emerged in the 1970s, but early candidates faced challenges like immunogenicity, inconsistent drug-antibody ratios, and premature payload release. Advances in recombinant DNA technology in the 1980s-90s allowed the production of humanized or fully human antibodies, reducing immune reactions. Modern ADCs rely on recombinant antibodies produced in mammalian cell systems (e.g., CHO cells) to ensure proper folding, glycosylation, and Fc-mediated functions. Recombinant methods also facilitate site-specific conjugation through engineered cysteine residues or non-natural amino acids, improving homogeneity compared to traditional random lysine-based conjugation.
Key innovations include trastuzumab emtansine (Kadcyla®), the first FDA-approved ADC using recombinant HER2-targeting antibodies, and newer platforms like cysteine-engineered mAbs for uniform drug loading. Recombinant proteins further enable bispecific ADCs and conditionally cleavable linkers to enhance tumor specificity. Challenges persist in optimizing antibody-drug ratios, linker stability, and scalable production, but recombinant technology continues to drive ADC evolution. Emerging trends include antibody fragments (e.g., scFv), alternative scaffolds, and AI-designed proteins to improve tumor penetration and pharmacokinetics. As biologics manufacturing advances, recombinant proteins remain pivotal in developing next-generation ADCs with enhanced therapeutic windows.
×
